Despite the improvements in the treatment of coronary artery disease (CAD) and acute
myocardial infarction (MI) over the past 20 years, ischemic heart disease (IHD) continues to …

Heart failure, a prevailing global health issue, imposes a substantial burden on both
healthcare systems and patients worldwide. With an escalating prevalence of heart failure …

Aims We assessed eligibility for omecamtiv mecarbil (OM) in a real-world cohort with heart
failure with reduced ejection fraction (HFrEF) according to the selection criteria of the …

Cardiovascular disease (CVD) is one of the leading causes of death worldwide. CVD
includes coronary artery diseases such as angina, myocardial infarction, and stroke.“Lipid …

Cardiovascular diseases stand as a leading cause of death worldwide, incurring substantial
medical costs and care. Despite significant advancements in diagnosing and treating these …

Heart failure with reduced ejection fraction (HFrEF) is a complex clinical syndrome with
significant morbidity and mortality and seems to be responsible for approximately 50% of …

Modulation of sarcomere contractility represents a new therapeutic opportunity for the
treatment of heart failure by directly targeting the thick and thin filament proteins of the …

正性肌力药物是治疗失代偿性心力衰竭的常用药物, 但慢性肾脏病患者如何选择与应用,
缺乏指导性意见. 本文在介绍不同种类正性肌力药物的药理作用基础上, 基于循证证据评价正性 …

As American clinicians have tried to reduce heart failure rehospitalizations and improve care
for patients with heart failure with reduced ejection fraction (HFrEF), the population of …

Methamphetamine (MA) use continues to rise worldwide. The adverse effects of MA on the
cardiovascular system include cardiomyopathy, dysrhythmias, coronary arterial vasospasm …